Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease
Clinical and Experimental Immunology · 2025
DOI: 10.1093/cei/uxae082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Lu Hui und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, West China Second University Hospital, and Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Bi…. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Inflammatory Bowel Diseases, Aminopyridines, Colitis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sichuan Science and Technology Program, Clinical Research Foundation of West China Second University Hospital.
Abstract (Originalsprache)
Amlexanox (ALX) is a small-molecule drug for the treatment of inflammatory, autoimmune, metabolic, and tumor diseases. At present, there are no studies on whether ALX has a therapeutic effect on inflammatory bowel disease (IBD). In this study, we used a mouse model of dextran sulfate sodium-induced colitis to investigate the effect of ALX-targeted inhibition of TBK1 on colitis. We found that the severity of colitis in mice was correlated with TBK1 expression. Notably, although ALX inhibited the activation of the TBK1-NF-κB/TBK1-IRF3 pro-inflammatory signaling pathway, it exacerbated colitis and reduced survival in mice. The results of drug safety experiments ruled out a relationship between this exacerbating effect and drug toxicity. In addition, ELISA results showed that ALX promoted the secretion of IL-1β and IFN-α, and inhibited the production of cytokines IL-6, TNF-α, IL-10, TGF-β, and secretory IgA. Flow cytometry results further showed that ALX promoted T-cell proliferation, activation, and differentiation, and thus played a pro-inflammatory role; also, ALX inhibited the generation of dendritic cells and the polarization of macrophages to M1 type, thus exerting anti-inflammatory effect. These data suggest that the regulation of ALX on the function of different immune cells is different, so the effect on the inflammatory response is bidirectional. In conclusion, our study demonstrates that simply inhibiting TBK1 in all immune cells is not effective for the treatment of colitis. Further investigation of the anti-inflammatory mechanism of ALX on dendritic cells and macrophages may provide a new strategy for the treatment of IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, West China Second University Hospital, and Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, Chi…
- State Key Laboratory of Biotherapy and Cancer Center/National Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
ORCID-Profile: Lu Hui, Chen-Xi Liu, Yong-Mei Jiang
Förderung
- Sichuan Science and Technology Program
- Clinical Research Foundation of West China Second University Hospital
Zitieren
APA
Hui, L., Huang, M. K., Dai, Q. K., Miao, C. L., Yang, Y. L., Liu, C. X., Liu, T., & Jiang, Y. M. (2025). Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae082
Vancouver
Hui L, Huang MK, Dai QK, Miao CL, Yang YL, Liu CX, et al. Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae082
BibTeX
@article{Hui2025,
author = {Hui, Lu and Huang, Meng-Ke and Dai, Qing-Kai and Miao, Cheng-Lin and Yang, Yun-Long and Liu, Chen-Xi and Liu, Ting and Jiang, Yong-Mei},
title = {Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease},
journal = {Clinical and Experimental Immunology},
year = {2025},
doi = {10.1093/cei/uxae082}
}
EUVIMED